BG107614A - РЕЦЕПТОР HA EDb - ФИБРОНЕКТИН-ДОМЕНИ - Google Patents
РЕЦЕПТОР HA EDb - ФИБРОНЕКТИН-ДОМЕНИ Download PDFInfo
- Publication number
- BG107614A BG107614A BG107614A BG10761403A BG107614A BG 107614 A BG107614 A BG 107614A BG 107614 A BG107614 A BG 107614A BG 10761403 A BG10761403 A BG 10761403A BG 107614 A BG107614 A BG 107614A
- Authority
- BG
- Bulgaria
- Prior art keywords
- protein
- edb
- cells
- seq
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10045803A DE10045803A1 (de) | 2000-09-07 | 2000-09-07 | Rezeptor der EDb Fibronektin-Domäne |
DE2001123133 DE10123133A1 (de) | 2001-05-02 | 2001-05-02 | Rezeptor der ED¶b¶-Fibronektin-Domäne (II) |
PCT/EP2001/010016 WO2002020563A2 (fr) | 2000-09-07 | 2001-08-30 | RECEPTEUR DU DOMAINE DE LA EDb-FIBRONECTINE |
Publications (1)
Publication Number | Publication Date |
---|---|
BG107614A true BG107614A (bg) | 2003-12-31 |
Family
ID=26007070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG107614A BG107614A (bg) | 2000-09-07 | 2003-03-06 | РЕЦЕПТОР HA EDb - ФИБРОНЕКТИН-ДОМЕНИ |
Country Status (24)
Country | Link |
---|---|
US (3) | US20020197700A1 (fr) |
EP (1) | EP1381629B1 (fr) |
JP (1) | JP2004529848A (fr) |
KR (1) | KR20030045056A (fr) |
CN (1) | CN1246333C (fr) |
AT (1) | ATE407951T1 (fr) |
AU (1) | AU1218202A (fr) |
BG (1) | BG107614A (fr) |
BR (1) | BR0113737A (fr) |
CA (1) | CA2421783A1 (fr) |
DE (1) | DE50114321D1 (fr) |
EE (1) | EE200300092A (fr) |
ES (1) | ES2312478T3 (fr) |
HK (1) | HK1064683A1 (fr) |
HR (1) | HRP20030263A2 (fr) |
HU (1) | HUP0300935A3 (fr) |
IL (1) | IL154778A0 (fr) |
NO (1) | NO20031033L (fr) |
NZ (1) | NZ524342A (fr) |
PL (1) | PL364358A1 (fr) |
RU (1) | RU2280254C2 (fr) |
SK (1) | SK2882003A3 (fr) |
WO (1) | WO2002020563A2 (fr) |
YU (1) | YU17503A (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001062800A1 (fr) | 2000-02-24 | 2001-08-30 | Eidgenössische Technische Hochschule Zürich | Anticorps specifique au domaine ed-b de la fibronectine, conjugues contenant cet anticorps, et utilisation pour la detection et le traitement de l'angiogenese |
US7785591B2 (en) * | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
BRPI0520677A2 (pt) | 2005-11-09 | 2009-05-19 | Bayer Schering Pharma Ag | identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina |
EP1892248A1 (fr) * | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Protéines liantes spécifiques et de haute affinité comprenant des domaines SH3 de FYN kinase modifiés |
EA018985B1 (ru) | 2007-04-02 | 2013-12-30 | Филоджен С.П.А. | Новый антиген, ассоциированный с новообразованными сосудами опухолевых метастазов |
US10202442B2 (en) | 2007-07-25 | 2019-02-12 | Philogen S.P.A. | Antigen associated with lung cancers and lymphomas |
KR101608544B1 (ko) | 2007-10-30 | 2016-04-01 | 필로겐 에스.피.에이. | 류마티스 관절염과 연관된 항원 |
EP2085095B1 (fr) * | 2008-01-17 | 2012-03-07 | Philogen S.p.A. | Combinaison de protéine de fusion anticorps de fibronectine anti-EDb-IL-2, et molécule se liant aux lymphocytes B, progéniteurs de lymphocytes B et/ou leur contrepartie cancéreuse |
WO2011015333A2 (fr) | 2009-08-05 | 2011-02-10 | Philogen S.P.A. | Ciblage de la néovascularisation de la moelle osseuse |
CN111329994A (zh) | 2012-10-03 | 2020-06-26 | 菲罗根股份公司 | 与炎性肠病有关的抗原 |
CN111148759B (zh) | 2017-09-30 | 2023-09-19 | 合肥立方制药股份有限公司 | 结合至纤维连接蛋白b结构域的蛋白 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4341223A (en) * | 1981-02-04 | 1982-07-27 | Lutz Lauralee A | Fluoresceable composition and method of determining fluid flow |
US4741900A (en) * | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US5576195A (en) * | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
US4894326A (en) * | 1986-04-09 | 1990-01-16 | Fred Hutchinson Cancer Research Center | Monoclonal antibody defining oncofetal structure of fibronectin |
US5243029A (en) * | 1986-04-09 | 1993-09-07 | Fred Hutchinson Cancer Research Center | Oncofetal structure of fibronectin |
EP0330506A3 (fr) * | 1988-02-26 | 1990-06-20 | Dana Farber Cancer Institute | Protéines VLA |
US5177015A (en) * | 1988-08-12 | 1993-01-05 | Fred Hutchinson Cancer Research Centre | Onco-developmentally regulated α-N-acetylgalactosaminyltransferase |
US5270030A (en) * | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
US5460785A (en) * | 1989-08-09 | 1995-10-24 | Rhomed Incorporated | Direct labeling of antibodies and other protein with metal ions |
DK0486622T3 (da) * | 1989-08-09 | 1999-07-19 | Rhomed Inc | Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium |
US5120830A (en) * | 1990-10-25 | 1992-06-09 | Washington University | Inhibitory peptides against α-2, β-1 mediated mg++ dependent adhesion of platelets to collagen |
US5629291A (en) * | 1992-01-31 | 1997-05-13 | La Jolla Cancer Research Foundation | Methods of modulating fibronectin extracellular matrix assembly |
AU675929B2 (en) * | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US6004555A (en) * | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
US6749853B1 (en) * | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US6036955A (en) * | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
US5877289A (en) * | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
US6093399A (en) * | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
US5976535A (en) * | 1992-06-09 | 1999-11-02 | Neorx Corporation | Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore |
WO1994007598A1 (fr) * | 1992-09-25 | 1994-04-14 | Otsuka Pharmaceutical Factory, Inc. | Adsorbant pour fibronectine cellulaire, separation et purification de fibronectine et purification du sang |
JP3339724B2 (ja) * | 1992-09-29 | 2002-10-28 | 株式会社リコー | インクジェット記録方法及びその装置 |
US5491130A (en) * | 1992-11-10 | 1996-02-13 | The United States Of America As Represented By The Department Of Health And Human Services | Peptide inhibitors of fibronectin and related collagen-binding proteins |
GB9324807D0 (en) * | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
US6015897A (en) * | 1993-12-07 | 2000-01-18 | Neorx Corporation | Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota |
US5523229A (en) * | 1994-03-22 | 1996-06-04 | Trustees Of The University Of Pennsylvania | Antibodies specific for oncofetal fibronectin |
DE4417865A1 (de) * | 1994-05-20 | 1995-11-23 | Behringwerke Ag | Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie |
US5648485A (en) * | 1994-10-26 | 1997-07-15 | University Of British Columbia | β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins |
DE4445065A1 (de) * | 1994-12-07 | 1996-06-13 | Diagnostikforschung Inst | Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung |
WO1997002479A2 (fr) * | 1995-06-30 | 1997-01-23 | Yale University | Anticorps anti-tumoraux monoclonaux humains |
US5808146A (en) * | 1995-11-09 | 1998-09-15 | Emory University | Amino acid analogs for tumor imaging |
GB9610967D0 (en) * | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
US5913884A (en) * | 1996-09-19 | 1999-06-22 | The General Hospital Corporation | Inhibition of fibrosis by photodynamic therapy |
US5842156A (en) * | 1996-11-12 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Air Force | Multirate multiresolution target tracking |
GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
US6267722B1 (en) * | 1998-02-03 | 2001-07-31 | Adeza Biomedical Corporation | Point of care diagnostic systems |
US6394952B1 (en) * | 1998-02-03 | 2002-05-28 | Adeza Biomedical Corporation | Point of care diagnostic systems |
US6296831B1 (en) * | 1998-04-10 | 2001-10-02 | Battelle Memorial Institute | Stimulus sensitive gel with radioisotope and methods of making |
US5997842A (en) * | 1998-04-13 | 1999-12-07 | Light Sciences Limited Partnership | Radionuclide excited phosphorescent material for administering PDT |
US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
US20030045681A1 (en) * | 1998-05-11 | 2003-03-06 | Anthony J. Zelano | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
TWI259837B (en) * | 1998-05-11 | 2006-08-11 | Eidgenossische Tech Hochscule | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
US20030176663A1 (en) * | 1998-05-11 | 2003-09-18 | Eidgenossische Technische Hochscule | Specific binding molecules for scintigraphy |
US6630570B1 (en) * | 1999-04-09 | 2003-10-07 | Insitut für Diagnostikforschung GmbH | Short-chain peptide-dye conjugates as contrast media for optical diagnosis |
US6171578B1 (en) * | 1999-04-14 | 2001-01-09 | Diatide, Inc. | Benzodiazepine derivatives for imaging thrombi |
KR100816572B1 (ko) * | 1999-04-28 | 2008-03-24 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 항-vegf 항체 및 이를 포함하는 약제학적 조성물 |
EP1267935A2 (fr) * | 2000-01-12 | 2003-01-02 | Light Sciences Corporation | Nouveau traitement pour maladie des yeux |
ES2269361T3 (es) * | 2000-02-24 | 2007-04-01 | Philogen S.P.A. | Composiciones y metodos para tratamiento de la angiogenesis en lesiones patologicas. |
US6342326B1 (en) * | 2000-05-10 | 2002-01-29 | Beckman Coulter, Inc. | Synthesis and use of acyl fluorides of cyanine dyes |
CN100589845C (zh) * | 2001-03-07 | 2010-02-17 | 麦康公司 | 用于治疗癌症的抗新血管系统制剂 |
WO2003008537A2 (fr) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Sequences d'epitope |
JP2005523887A (ja) * | 2002-01-03 | 2005-08-11 | シエーリング アクチエンゲゼルシャフト | 腫瘍の新しい診断および治療方法 |
AR040956A1 (es) * | 2002-07-31 | 2005-04-27 | Schering Ag | Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico |
-
2001
- 2001-08-30 KR KR10-2003-7003340A patent/KR20030045056A/ko active IP Right Grant
- 2001-08-30 CN CNB018153461A patent/CN1246333C/zh not_active Expired - Fee Related
- 2001-08-30 EP EP01980305A patent/EP1381629B1/fr not_active Expired - Lifetime
- 2001-08-30 AT AT01980305T patent/ATE407951T1/de not_active IP Right Cessation
- 2001-08-30 ES ES01980305T patent/ES2312478T3/es not_active Expired - Lifetime
- 2001-08-30 PL PL01364358A patent/PL364358A1/xx not_active Application Discontinuation
- 2001-08-30 RU RU2003109431/13A patent/RU2280254C2/ru not_active IP Right Cessation
- 2001-08-30 HU HU0300935A patent/HUP0300935A3/hu unknown
- 2001-08-30 BR BR0113737-9A patent/BR0113737A/pt not_active IP Right Cessation
- 2001-08-30 DE DE50114321T patent/DE50114321D1/de not_active Expired - Lifetime
- 2001-08-30 YU YU17503A patent/YU17503A/sh unknown
- 2001-08-30 NZ NZ524342A patent/NZ524342A/en unknown
- 2001-08-30 AU AU1218202A patent/AU1218202A/xx active Pending
- 2001-08-30 IL IL15477801A patent/IL154778A0/xx unknown
- 2001-08-30 US US09/942,117 patent/US20020197700A1/en not_active Abandoned
- 2001-08-30 CA CA002421783A patent/CA2421783A1/fr not_active Abandoned
- 2001-08-30 EE EEP200300092A patent/EE200300092A/xx unknown
- 2001-08-30 WO PCT/EP2001/010016 patent/WO2002020563A2/fr active IP Right Grant
- 2001-08-30 JP JP2002525182A patent/JP2004529848A/ja active Pending
- 2001-08-30 SK SK288-2003A patent/SK2882003A3/sk unknown
-
2003
- 2003-03-06 NO NO20031033A patent/NO20031033L/no not_active Application Discontinuation
- 2003-03-06 BG BG107614A patent/BG107614A/bg unknown
- 2003-04-07 HR HR20030263A patent/HRP20030263A2/hr not_active Application Discontinuation
- 2003-10-02 US US10/676,049 patent/US20050089941A1/en not_active Abandoned
-
2004
- 2004-09-28 HK HK04107490A patent/HK1064683A1/xx not_active IP Right Cessation
-
2005
- 2005-04-14 US US11/105,475 patent/US20050221434A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20050089941A1 (en) | 2005-04-28 |
RU2280254C2 (ru) | 2006-07-20 |
CA2421783A1 (fr) | 2002-03-14 |
CN1246333C (zh) | 2006-03-22 |
NZ524342A (en) | 2005-09-30 |
ES2312478T3 (es) | 2009-03-01 |
CN1487953A (zh) | 2004-04-07 |
YU17503A (sh) | 2006-05-25 |
US20020197700A1 (en) | 2002-12-26 |
RU2003109431A (ru) | 2005-01-20 |
PL364358A1 (en) | 2004-12-13 |
HUP0300935A2 (hu) | 2003-12-29 |
WO2002020563A2 (fr) | 2002-03-14 |
HUP0300935A3 (en) | 2005-09-28 |
WO2002020563A3 (fr) | 2003-10-09 |
ATE407951T1 (de) | 2008-09-15 |
JP2004529848A (ja) | 2004-09-30 |
IL154778A0 (en) | 2003-10-31 |
SK2882003A3 (en) | 2003-08-05 |
EP1381629A2 (fr) | 2004-01-21 |
AU1218202A (en) | 2002-03-22 |
US20050221434A1 (en) | 2005-10-06 |
HK1064683A1 (en) | 2005-02-04 |
BR0113737A (pt) | 2004-02-25 |
EP1381629B1 (fr) | 2008-09-10 |
DE50114321D1 (de) | 2008-10-23 |
NO20031033L (no) | 2003-05-07 |
NO20031033D0 (no) | 2003-03-06 |
EE200300092A (et) | 2005-06-15 |
HRP20030263A2 (en) | 2005-10-31 |
KR20030045056A (ko) | 2003-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5607918A (en) | Vascular endothelial growth factor-B and DNA coding therefor | |
KR101569083B1 (ko) | Vegfr-2와 dll4를 표적으로 하는 이중표적항체 및 이를 포함하는 약학적 조성물 | |
Camussi et al. | Angiogenesis induced in vivo by hepatocyte growth factor is mediated by platelet-activating factor synthesis from macrophages. | |
An et al. | Suppression of tumor growth and metastasis by a VEGFR‐1 antagonizing peptide identified from a phage display library | |
RU2146262C1 (ru) | Пептиды, способ их получения, фармацевтическая композиция и способ ее получения | |
US20050221434A1 (en) | Receptor of the EDb-fibronectin domains | |
JP5089397B2 (ja) | 変異ネトリン4、その断片及びこれらの薬剤としての使用 | |
US7575751B2 (en) | Activin-A mutants | |
BRPI0410963B1 (pt) | anticorpo que especificamente se liga a uma região no fator de crescimento do tecido conjuntivo humano, anticorpo quimérico, composição farmacêutica, uso de um anticorpo, par de polinucleotídeos, polinucleotídeo recombinante, e, microrganismo | |
US20170276688A1 (en) | Anti-himf antibodies to treat lung diseases | |
KR20120137270A (ko) | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 | |
Su et al. | Bruton's tyrosine kinase (BTK) is a binding partner for hypoxia induced mitogenic factor (HIMF/FIZZ1) and mediates myeloid cell chemotaxis | |
Stoletov et al. | Nck and Crk mediate distinct VEGF-induced signaling pathways that serve overlapping functions in focal adhesion turnover and integrin activation | |
EP1332761A1 (fr) | Agonistes des récepteurs du facteur de croissance des fibroblastes | |
US20130089548A1 (en) | Method and compositions to induce apoptosis of tumoral cells expressing shh | |
JP2008013436A (ja) | 血管形成促進剤 | |
US6462170B1 (en) | UPAR mimicking peptide | |
ZA200302629B (en) | Receptor in the EDb fibronectin domain. | |
US20090214495A1 (en) | Vascular endothelial growth factor-d (vegf)-d and functionally fragments thereof for bone repairing | |
You | Studies on the functions of Latent Transforming Growth Factor β (TGF-β) binding protein-2 (LTBP-2) in the regulation of TGF-β 1 and fibrosis progression | |
DE10123133A1 (de) | Rezeptor der ED¶b¶-Fibronektin-Domäne (II) | |
Kemp | Focal adhesion kinase signalling in endothelial cells | |
Stoletov | Role of Nck and Crk adapter proteins in the VEGF promoted endothelial cell migration | |
Shekarabi | Netrin-1 signaling: cellular consequences and molecular mechanisms | |
KR20080083072A (ko) | Vegf-x 또는 그의 길항제에 의한 평활근 세포 증식의 조절 |